There was a significant difference in the time to start of new treatment , with 46 % ( 95 % CI 39-53 ) of patients in the watchful waiting group not needing treatment at 3 years compared with 88 % ( 83-92 ) in the maintenance rituximab group ( hazard ratio [ HR ] 021 , 95 % CI 014-031 ; p < 00001 ) .